X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EVO756 is a potent, highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2). It is under phase 1 clinical development for the treatment of chronic spontaneous urticaria.
Lead Product(s): EVO756
Therapeutic Area: Immunology Product Name: EVO756
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
The collaboration will leverage Accutar's proprietary AI platform as well as Evommune's expertise in the design and development of novel oral small molecule treatments against targets that are the root cause of chronic immune-mediated inflammatory diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: AccutarBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 28, 2023
Details:
The collaboration aims to develop and commercialize EVO756 in Japan. Evommune’s MRGPRX2 antagonist, is an investigational therapy with the potential to be a first-in-class oral treatment for a variety of mast cell mediated disease.
Lead Product(s): EVO756
Therapeutic Area: Immunology Product Name: EVO756
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maruho
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2023
Details:
In the Phase 2a study, AD patients will apply EVO101 cream twice daily for eight weeks. Primary efficacy will be assessed by changes from baseline in the Eczema Area and Severity Index (EASI).
Lead Product(s): EVO101
Therapeutic Area: Dermatology Product Name: EVO101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2022
Details:
EVO101 is a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) which broadly inhibits innate inflammation and is being developed as a treatment for inflammatory skin diseases.
Lead Product(s): EVO101
Therapeutic Area: Dermatology Product Name: EVO101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
The financing will allow to advance four programs of Evommune in pipeline among which three of the compounds include IRAK4/TrkA, broadly inhibits innate inflammation; RORγt, treating inflammation; MRGPRX2, to treat chronic pruritus and fourth compound is a PKCtheta inhibitor.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Andera Partners
Deal Size: $83.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 09, 2021
Details:
Agreement aims to develop and commercialize three development programs for the treatment of various inflammatory diseases which include IRAK4/TrkA; RORγt; and MRGPRX2.
Lead Product(s): Undisclosed
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
